| | | | |
Unadjusted
|
Adjusted
b
|
Adjusted
b
|
---|
|
G1m genotype
a
|
number
|
Baseline DAS28
|
ΔDAS28
|
Beta
|
P-value
|
Beta
|
P-value
|
---|
All patients
|
G1m1,17+
|
92
|
5.9 ± 1.1
|
2.3 ± 1.6
|
0.20
|
0.006
|
0.14
|
0.02
|
|
G1m1,17-
|
94
|
5.7 ± 1.1
|
1.6 ± 1.5
| | | | |
INX
|
G1m1,17+
|
68
|
5.9 ± 1.1
|
2.1 ± 1.6
|
0.16
|
0.06
|
0.16
|
0.03
|
|
G1m1,17-
|
72
|
5.8 ± 1.1
|
1.6 ± 1.5
| | | | |
ADM
|
G1m1,17+
|
24
|
6.1 ± 1.3
|
2.9 ± 1.5
|
0.32
|
0.03
|
0.16
|
0.19
|
|
G1m1,17-
|
22
|
5.6 ± 1.4
|
1.9 ± 1.5
| | | | |
-
aCarrier status; banalyses adjusted for baseline DAS28, gender and RF (and anti-TNF for All patients). ADM, adalimumab; anti-TNF, anti-tumor necrosis factor; DAS28, disease activity score in 28 joints; INX, infliximab; RF, rheumatoid factor.